(4890) Stock Price

Tsubota Lab is a venture company spun out from Keio University School of Medicine that develops treatments targeting myopia, dry eye, presbyopia, and brain diseases. Founded in 2012, the company aims to deliver research outcomes to society. Myopia, dry eye, and presbyopia are recognized as areas with high unmet medical needs, with millions of patients worldwide.

Tsubota Lab specializes in research and development operations and operates as a single business segment. Its primary research partner is Keio University, and it has established partnerships with companies including Jins Holdings and Rohto Pharmaceutical. Through these collaborations, the company aims to bring research outcomes to market.

Tsubota Lab's business model is a circular innovation model in which revenue from joint research and development contracts and implementation licensing agreements with partner companies is reinvested into new research and development. The company conducts basic research through early-stage clinical trials, with partner companies advancing later-stage clinical trials toward commercialization.

In the myopia field, the company discovered that violet light effectively suppresses myopia progression and has developed products including "TLG-001," a glasses-frame medical device, and "TLM-003," an eye drop with a novel mechanism. These products aim to inhibit myopia progression.

In the dry eye field, the company is developing glasses-type devices and functional supplements designed to improve tear film stability. These aim to reduce dry eye symptoms and enhance visual function quality.

In the presbyopia field, the company focuses on age-related lens changes and conducts research and development of pharmaceuticals and related products through metabolic regulation. Presbyopia is an age-related accommodation disorder that frequently impairs daily life.

In the brain disease field, the company is researching violet light's potential to increase cerebral blood flow, targeting depression, Parkinson's disease, and mild cognitive impairment. This explores new therapeutic possibilities.

Tsubota Lab is pursuing multifaceted research on medical applications of violet light, including applications in posterior segment diseases, keratoconus treatment, and circadian rhythm adjustment. The company is also considering expansion into veterinary medicine.

Tsubota Lab's fundamental strategy is to address social challenges from a long-term perspective. The company aims to create innovative solutions through proprietary inventions that lead to patents and collaboration with partner companies. This approach pursues CSV management—creating both social and economic value simultaneously—to achieve sustainable growth.

The company prioritizes strengthening basic research and intellectual property management, focusing research and development on high unmet medical needs in areas such as myopia, dry eye, presbyopia, and neurological diseases. Through joint development with partner companies, the company aims to build a business model that realizes product commercialization and generates royalty income.

Strengthening business development domestically and internationally is also a key strategic component. Tsubota Lab builds a circular model based on proprietary technology and intellectual property, establishing joint research and development agreements and licensing contracts with partner companies, then reinvesting revenues into new research and development. This approach enhances the quality and efficiency of research and development while expanding corporate value.

The company also emphasizes strengthening regulatory science capabilities. To obtain regulatory approval from authorities in each country for research and development outcomes, the company is building internal expertise and establishing systems capable of responding to global development and approval strategies. This enables commercialization and contributes to society.

In strengthening corporate capabilities, the company has adopted OKR (Objectives and Key Results) to establish goal-setting and progress management systems directly linked to its vision and mission. This aligns strategy with operations, accelerates decision-making, and visualizes results, thereby strengthening corporate capabilities.

Tsubota Lab promotes joint research with domestic and international universities and research institutions, including Keio University, and builds networks with academia by leveraging the T-SBIR program. This enables early identification of cutting-edge research themes and aims to accelerate research and development and early commercialization.